about
Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugsSolution Structures of a DNA Dodecamer Duplex with and without a Cisplatin 1,2-d(GG) Intrastrand Cross-Link: Comparison with the Same DNA Duplex Containing an Oxaliplatin 1,2-d(GG) Intrastrand Cross-Link † , ‡The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozymeThe X-ray structure of the primary adducts formed in the reaction between cisplatin and cytochrome cCisplatin encapsulation within a ferritin nanocage: a high-resolution crystallographic studyNanocarriers for delivery of platinum anticancer drugs.Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model.Association of childhood acute lymphoblastic leukaemia with cancers in family membersIdentification of pathways controlling DNA damage induced mutation in Saccharomyces cerevisiae.Secondary Primary Malignancy Risk in Patients With Cervical Cancer in Taiwan: A Nationwide Population-Based Study.Inflammation-driven carcinogenesis is mediated through STINGSolid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.Assessment of anti-mutagenic, anti-histopathologic and antioxidant capacities of Egyptian bee pollen and propolis extracts.Comparison of the cytotoxic effects of Juniperus sabina and Zataria multiflora extracts with Taxus baccata extract and Cisplatin on normal and cancer cell lines.Mutagenesis in monkey cells of a vector containing a single d(GPG) cis-diamminedichloroplatinum(II) adduct placed on codon 13 of the human H-ras proto-oncogene.Human papillomavirus type 16-immortalized endocervical cells selected for resistance to cisplatin are malignantly transformed and have a multidrug resistance phenotype.Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions.Esophageal cancer developed in a radiated field: can we reduce the risk of a poor prognosis cancer?Adolescents and young adults with a "rare" cancer: getting past semantics to optimal care for patients with germ cell tumorsMolecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamicsIn vitro bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase beta and human immunodeficiency virus type I reverse transcriptase is highly mutagenic.Risk of second primary cancers in cancer patients treated with cisplatin: a systematic review and meta-analysis of randomized studies.Synthesis and antiproliferative activity of a series of new platinum and palladium diphosphane complexes.X-ray Structure of the Carboplatin-Loaded Apo-Ferritin Nanocage.Thermodynamics of translesion synthesis across a major DNA adduct of antitumor oxaliplatin: differential scanning calorimetric study.Incorporation of cisplatin into the metal–organic frameworks UiO66-NH2 and UiO66 – encapsulation vs. conjugationRisk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer
P2860
Q24644933-125A1897-F159-4D06-8337-903DD0EAAD87Q27644753-9BCB5D2A-5CE0-4401-B156-5E6537F9C925Q27690763-12AED259-EC41-47DE-84C6-3918C5F289B4Q27697308-E9D32500-A997-43D3-B60D-0411DBA7A9B2Q27704043-7CA168A9-2CD8-4BAF-B0AA-80D2C6DD0B56Q34338695-8A1283B0-0540-4ED6-8E2C-3FF54D5A07C5Q34346562-1189B0CF-F286-4151-8BFA-0F259552BC78Q36614974-5D8E003C-07EA-405C-8AA9-79402C3291CCQ36740419-34467AED-C216-4FBE-8EA0-41282BB6A6CFQ37176188-3785DB05-141D-412A-8F43-A0334EEAB71EQ37207341-13A19C6A-3FF5-45FB-9E6A-8364BFFFC023Q37227682-B1C38195-C11B-4284-998D-306768DCE6C1Q37569435-079E8834-6A60-458D-9D17-8BCEF826506CQ39674090-CACDDABB-5588-489F-974A-091FB2146753Q40400417-0432FBE3-CA77-4917-80DE-F1DAF5825DAEQ40859204-82B998E8-CE64-41F4-B170-07815A7F01F4Q41142052-BAE93F28-4047-472C-8A26-49B36845C2C2Q42341982-D1CE537F-24AA-48A4-A374-C9EC5C95045BQ42716527-C93CF02E-DEED-407A-A2FE-2CF267D35261Q42789116-B4460EA1-C0DF-4C1F-B311-7CA4B801A574Q45770163-968C75EC-E8E0-4C0F-B42E-2A0C97D08747Q47100585-48E81175-929C-4410-A3DE-F804EF85CE03Q50015963-33CC84C4-5CE6-43DB-8801-0ED21FAAB196Q50905102-EEFAEBF9-6C6C-4337-98EB-C90D84FFBD94Q50975254-9C155D2E-98F2-46E6-9E5F-1A82B26CED53Q57385191-15656F5D-76E4-4647-A96D-216DFC55AEB0Q58411595-AC50ADEC-A78E-4363-8067-9134D1E0AFDD
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի մարտին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Is cisplatin a human carcinogen?
@ast
Is cisplatin a human carcinogen?
@en
Is cisplatin a human carcinogen?
@nl
type
label
Is cisplatin a human carcinogen?
@ast
Is cisplatin a human carcinogen?
@en
Is cisplatin a human carcinogen?
@nl
prefLabel
Is cisplatin a human carcinogen?
@ast
Is cisplatin a human carcinogen?
@en
Is cisplatin a human carcinogen?
@nl
P356
P1476
Is cisplatin a human carcinogen?
@en
P2093
P304
P356
10.1093/JNCI/84.5.306
P407
P577
1992-03-01T00:00:00Z